Eli Lilly CEO says Medicare price negotiations could harm drug development

Ricks said the "biggest problem" with the IRA provision stems from a difference in timeline for negotiating prices on two different types of drugs.

from Health and Science https://ift.tt/mwkOiHe
https://ift.tt/qQvPOyp
https://ift.tt/lBTn2eL